降糖版司美格鲁肽致眼部并发症?诺和诺德:不属于已获批药物的不良反应

时代财经
19 Feb

本文来源:时代财经 作者:张羽岐图片来源:图虫创意《美国医学会杂志-眼科学》发布的一篇研究论文引发争议,其指出患者在使用诺和诺德降糖版司美格鲁肽(商品名:Ozempic)或礼来制药降糖版替尔泊肽(商品名:Mounjaro)之后出现眼部并发症。对上述论文原文所指出的情况,诺和诺德对时代财经回应称,该研究并不能证实包括司美格鲁肽在内的这类药物与所报告的眼部并发症之间存在因果关系。诺和诺德进一步对时代...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10